LOGIN  |  REGISTER
Astria Therapeutics

Latest Medical Stock News

FILTER BY TOPIC:     Medical Devices   Diagnostics & Research   FDA 510(k) Clearance   Psychedelics        List of All Medical Stocks  

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

June 21
Last Trade: 4.58 -0.09 -2.02

91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or Improved No Ulcer Recurrences Company on Track to File Application Seeking VenoValve FDA Approval in Q4...Read more


Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of...Read more


Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement

June 21
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the second and final tranche ("Final Tranche") of its previously announced $1,000,0000 non-brokered private placement (the "Offering"). Under...Read more


Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

June 20
Last Trade: 115.74 -0.33 -0.28

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2 New Dexcom G7 automated insulin delivery integrations* further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7 app updates,...Read more


Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

June 20
Last Trade: 200.99 1.68 0.84

Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S. Omnipod 5 App for iPhone begins limited market release in the U.S. ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump...Read more


Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

June 20
Last Trade: 200.99 1.68 0.84

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible...Read more


Radiopharm Receives Strategic Investment for up to A$18 million

June 20
Last Trade: 79.52 -1.96 -2.41

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option for Lantheus to invest a further A$7.5m within 6 months on the same terms Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development...Read more


Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

June 20
Last Trade: 42.90 0.33 0.78

SAN DIEGO / Jun 20, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude “JC” Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare...Read more


ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

June 20
Last Trade: 5.60 0.06 1.08

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells (DANPCs) for all enrolled patients with Parkinson’s Disease (PD)...Read more


Allurion Technologies Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

June 20
Last Trade: 2.20 -0.40 -15.39

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11%1 NATICK, Mass. / Jun 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at...Read more


Theralase Technologies: Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy

June 20
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

June 20
Last Trade: 1.18 -0.09 -7.09

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products. The four products –...Read more


NeuroOne Medical Technologies Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation

June 20
Last Trade: 0.83 -0.0028 -0.34

ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system EDEN PRAIRIE, Minn., June 20, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving...Read more


Numinus Wellness Announces Strategic Acquisition of MedBright AI

June 20
Last Trade: 0.05 -0.005 -9.09

Plans name change to "Numinus Intelligence" leveraging its current revenue-generating operations to AI-enable mental health clinics across the U.S. The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus' deep data and vast experience with drug-assisted mental health treatment to improve clinical operations and capitalize on reimbursable offerings Leaders from MedBright AI team with...Read more


Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

June 20
Last Trade: 2.05 0.95 86.32

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.  The newly issued...Read more


Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

June 20
Last Trade: 1.02 -0.005 -0.49

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory Readiness in Support of Trial BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic medical center...Read more


Critical Path and Centogene MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

June 20
Last Trade: 0.40 -0.01 -2.47

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development...Read more


Applied DNA Sciences and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

June 20
Last Trade: 0.46 -0.02 -3.61

Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a...Read more


First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion

June 20
Last Trade: 1.32 0.04 3.12

Reminder: Management “CEO Chat” with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time BURLINGTON, Mass. / Jun 20, 2024 / Business Wire / Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the...Read more


Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics

June 19
Last Trade: 252.69 4.13 1.66

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13...Read more


Theralase Technologies: Rutherrin Demonstrates Complete Response in Lung Cancer Preclinically

June 19
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation,...Read more


Boston Scientific Announces Agreement to Acquire Silk Road Medical

June 18
Last Trade: 77.28 0.28 0.36

Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a...Read more


Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device

June 18
Last Trade: 85.96 0.46 0.54

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a...Read more


Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions

June 18
Last Trade: 42.90 0.33 0.78

SAN DIEGO / Jun 18, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its schedule of presentations for the American Diabetes Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Product Theater The Company will host a Product Theater on Saturday, June 22 from 10:15 am - 11:00 am EDT at Product Theater...Read more


Milestone Scientific Receives Regulatory Approval to Market CompuFlo® Epidural System in Brazil

June 18
Last Trade: 0.69 0.02 2.24

Brazil is the 9th largest economy in the world with more than 21 million people suffering from chronic back pain An estimated 4-5 million epidural anesthesia procedures are performed annually in Brazil; potential to expand this addressable market due to CompuFlo’s technological advantages ROSELAND, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug...Read more


Theralase Technologies: Rutherrin Increases Efficacy of Immunotherapy Preclinically

June 18
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

June 18
Last Trade: 0.19 -0.01 -5.13

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's test for...Read more


Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

June 18
Last Trade: 1.91 0.04 2.14

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and sampling study...Read more


Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

June 18
Last Trade: 0.61 0.02 2.69

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer...Read more


Tivic Health: Christina Valauri Appointed to Board of Directors

June 18
Last Trade: 0.40 0.01 2.64

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team SAN FRANCISCO / Jun 18, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a...Read more


Prenetics Global Announces First Quarter 2024 Financial Results

June 18
Last Trade: 5.96 -0.13 -2.13

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the...Read more


Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

June 17
Last Trade: 206.00 -1.38 -0.67

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical...Read more


Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

June 17
Last Trade: 107.81 0.61 0.57

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejection AUSTIN, Texas / Jun 17, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant...Read more


Charles River Laboratories and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

June 17
Last Trade: 211.05 1.41 0.67

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial WILMINGTON, Mass. / Jun 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP),...Read more


Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

June 17
Last Trade: 15.01 -0.08 -0.53

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care VAUGHAN, Ontario / Jun 17, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society...Read more


iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

June 17
Last Trade: 105.17 -0.20 -0.19

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and...Read more


Elutia Announces $13.26 Million Registered Direct Offering

June 17
Last Trade: 3.60 0.12 3.45

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per...Read more


Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

June 17
Last Trade: 3.60 0.12 3.45

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”),...Read more


New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

June 17
Last Trade: 4.58 -0.09 -2.02

IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation,...Read more


Inspira Technologies Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

June 17
Last Trade: 1.33 -0.07 -4.93

RA'ANANA, Israel, June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce today that the Company will present at the annual iECOs Conference in Herzliya, Israel on June 18th, 2024. The Company will present the INSPIRA™ ART100 System, recently 510(k) U.S. Food and Drug...Read more


Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

June 17
Last Trade: 1.04 0.01 0.97

Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso’s Board SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. “We are...Read more


Avinger Announces Closing of up to $24 Million Public Offering

June 17
Last Trade: 1.90 -0.01 -0.53

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 17, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the...Read more


Helius Medical Technologies Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

June 17
Last Trade: 0.97 0.0074 0.77

Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke  In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke  NEWTOWN, Pa.,...Read more


Co-Diagnostics Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

June 14
Last Trade: 1.48 0.03 1.72

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...Read more


Join Sharps Technology’s Exclusive Live Investor Webinar and Q&A Session on June 18

June 14
Last Trade: 0.27 -0.02 -6.95

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Robert Hayes, CEO of Sharps Technology, who will share insight into the...Read more


Qiagen’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

June 13
Last Trade: 41.51 -0.38 -0.91

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels...Read more


Senseonics to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

June 13
Last Trade: 0.39 0.0001 0.03

GERMANTOWN, Md. / Jun 13, 2024 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL. Breakfast and...Read more


Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

June 13
Last Trade: 1.25 0.00 0.00

NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications, by providing long-term therapeutic delivery of exenatide for six months Study will represent first clinical application of NanoPortal™, the company’s proprietary, implant platform technology ALAMEDA, Calif. / Jun 13, 2024 / Business Wire / Vivani Medical, Inc....Read more


NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature...Read more


Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

June 13
Last Trade: 1.08 -0.01 -0.95

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods. Revenue for...Read more


CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union

June 13
Last Trade: 0.81 0.02 2.23

PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the launch and immediate availability of its PuriFi™ hemoperfusion machine in the E.U., following approval and certification under the E.U. Medical Device...Read more


Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion

June 13
Last Trade: 0.38 -0.73 -65.87

Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health...Read more


Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

June 13
Last Trade: 2.05 0.95 86.32

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices. Mark White, CEO of Nexalin Technology,...Read more


PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

June 13
Last Trade: 0.84 -0.01 -1.58

First patients enrolled on the Veris Cancer Care Platform NEW YORK, June 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University...Read more


Applied DNA Sciences Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

June 13
Last Trade: 0.46 -0.02 -3.61

STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and...Read more


IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

June 12
Last Trade: 215.43 1.24 0.58

Bold initiative to boost the capacity of research sites enters Beta testing and piloting RESEARCH TRIANGLE PARK, N.C. / Jun 12, 2024 / Business Wire / IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting. Clinical...Read more


RevelAi Health and Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity through AI-Powered Technology

June 12
Last Trade: 106.68 0.42 0.40

DURHAM, N.C. and WARSAW, Ind., June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi...Read more


Smith+Nephew personalizes robotic-assisted surgery for patients and surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services exclusively for the CORI™ Surgical System

June 12
Last Trade: 25.36 0.11 0.44

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System - the only orthopaedic robotic-assisted system to offer either intraoperative image-free...Read more


Accuray Announces Approval of the Accuray Precision® Treatment Planning System by China's National Medical Products Administration

June 12
Last Trade: 1.87 0.04 2.19

MADISON, Wis., June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams...Read more


Theralase Technologies: Rutherrin(R) Increases Efficacy of Chemotherapy

June 12
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead...Read more


Positive Data from IceCure Medical's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

June 12
Last Trade: 0.74 -0.0056 -0.75

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quarter of 2024, including data on patients with an average follow up of approximately 3 years  $6.92 billion global kidney cancer treatment market in 2024 expected to reach $8.78 billion by 2029—ProSense® is approved for the...Read more


Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market

June 12
Last Trade: 0.98 -0.01 -1.13

REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. Someone in the world dies of cardiovascular disease (CVD) every 1.5 seconds. In the...Read more


Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024

June 12
Last Trade: 0.19 -0.01 -5.13

Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place...Read more


Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

June 12
Last Trade: 2.24 -0.14 -5.88

Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory Services to Fuel Growth Prospects LITTLETON, Colo., June 12, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a...Read more


Qiagen launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance

June 11
Last Trade: 41.51 -0.38 -0.91

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide...Read more


RadNet to Present at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th

LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th at 12:15 p.m....Read more


Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

June 11
Last Trade: 24.21 0.41 1.72

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively...Read more


Nevro to Present at Truist Securities MedTech Conference

June 11
Last Trade: 8.89 0.30 3.49

REDWOOD CITY, Calif., June 11, 2024  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:40 am EDT. A...Read more


Allurion Technologies Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

June 11
Last Trade: 2.20 -0.40 -15.39

New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes NATICK, Mass. / Jun 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13,...Read more


Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

June 11
Last Trade: 2.40 0.00 0.00

WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger...Read more


Owlet Expands Global Footprint with Launch of Medically-Certified Dream Sock™ in the UK and Across Europe

June 11
Last Trade: 4.50 0.14 3.21

LEHI, Utah / Jun 11, 2024 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the UK and European launch of Dream Sock, a smart baby monitor with live health readings and notifications for healthy infants between 0-18 months and 2.5-13.6 kg. This innovative medical device provides parents with real-time health and vital information, offering unparalleled peace of...Read more


Meihua International Medical Technologies to Present at the Sidoti Small Cap Conference and Update Investors at the Emerging Growth Conference on June 13, 2024

June 11
Last Trade: 0.85 0.01 1.64

YANGZHOU, China, June 11, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, is pleased to announce that its management team will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, and will provide an update at the...Read more


NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

June 11
Last Trade: 2.00 -0.07 -3.38

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health....Read more


Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

June 11
Last Trade: 1.07 -0.06 -5.31

Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 20301 PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics,...Read more


Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems

June 10
Last Trade: 105.64 -0.93 -0.87

Abbott's consumer biowearable, Lingo™, is designed for general consumers who are looking to improve their overall health and wellness Libre Rio™ is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications Both products are based on FreeStyle Libre® sensing technology, the world's most widely used1 continuous glucose monitoring (CGM) systems, pioneered by Abbott...Read more


ResMed: PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

June 10
Last Trade: 209.96 -3.31 -1.55

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health. From exploration into the prevalence of...Read more


Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

June 10
Last Trade: 15.01 -0.08 -0.53

VAUGHAN, Ontario / Jun 10, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company’s proprietary OpticAlign® design, INFUSE for...Read more


Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

June 10
Last Trade: 10.19 -0.46 -4.32

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June...Read more


Surmodics Awarded Thrombectomy Products Agreement with Premier

June 10
Last Trade: 41.94 -0.02 -0.05

Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. EDEN PRAIRIE, Minn. / Jun 10, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective...Read more


PacBio and International Research Consortium CoLoRS Announce Release of First-Ever HiFi Long-Read Variant Database

June 10
Last Trade: 1.53 -0.04 -2.65

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease Research MENLO PARK, Calif., June 10, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), today announced the launch of the first publicly...Read more


Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing™ to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata

June 10
Last Trade: 1.19 -0.12 -9.16

BRANFORD, Conn. / Jun 10, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024. The...Read more


BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

June 10
Last Trade: 6.17 -0.06 -0.96

BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the initiation of a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company’s proprietary Deep Transcranial Magnetic...Read more


Theralase Technologies: Ruvidar(TM) Enhances Efficacy of Cancer Drug

June 10
Last Trade: 0.18 -0.005 -2.70

TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead compound, RuvidarTM, when combined...Read more


MIT Selects Movano Health for Groundbreaking Study on Long COVID and Chronic Lyme Disease

June 10
Last Trade: 0.38 -0.73 -65.87

Pioneering partnership advances innovative health monitoring, setting the stage for future enterprise opportunities. PLEASANTON, Calif., June 10, 2024 /PRNewswire/ -- In a strategic move that could reshape the understanding of long COVID and chronic Lyme disease, the Massachusetts Institute of Technology (MIT) has forged a partnership with Movano Health for its MAESTRO study to harness the medical grade continuous health monitoring...Read more


Therma Bright Closes $854,500 First Tranche of Non-Brokered Private Placement

June 10
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the first tranche ("First Tranche") of its previously announced non-brokered private placement (the "Offering"). Under the First Tranche, Therma...Read more


BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

June 10
Last Trade: 0.33 -0.14 -29.72

Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified...Read more


RadNet to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:40...Read more


Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ

June 7
Last Trade: 0.33 0.0009 0.28

KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”)...Read more


Cutera® Announces AviClear® Investor Webinar

June 7
Last Trade: 1.55 -0.12 -6.93

BRISBANE, Calif. / Jun 07, 2024 / Business Wire / CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market...Read more


Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

June 7
Last Trade: 0.05 -0.005 -9.09

VANCOUVER, BC, June 7, 2024 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a leader in mental health care specializing in innovative and evidence-based treatments, comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC"). The independent committee reviewed Lykos Therapeutics' new drug application for...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Medical Gainers

 
CompanyChangeLast Trade
Thermo Fisher Scientific 6.16 1.11 $563.37
Danaher 4.08 1.64 $252.64
Prestige Healthcare 2.93 4.49 $68.21
ICON 2.76 0.87 $318.76
Repligen 2.49 2.08 $122.49
Penumbra 2.29 1.31 $177.74
Masimo 2.03 1.56 $132.42
McKesson 1.71 0.28 $604.95
Insulet 1.66 0.83 $200.98
Edwards Lifesciences 1.57 1.77 $90.41
Atrion 1.25 0.28 $451.25
Twist Bioscience 1.19 2.44 $49.93
Exact Sciences 1.03 2.34 $45.03
Nexalin Technology 1.01 91.36 $2.11
IQVIA 0.96 0.45 $215.15
Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE
List of Medical Stocks

Medical Stocks

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB